Journal of International Reproductive Health/Family Planning ›› 2020, Vol. 39 ›› Issue (2): 163-166.

Previous Articles     Next Articles

Assisted Pregnancy Strategy for Patients with Clomiphene-Resistant Polycystic Ovary Syndrome

WANG Bao-juan,SONG Jia-yi,GONG Zheng,XIA Tian,MA Rui-hong   

  1. Reproductive Center,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300381,China
  • Received:2019-12-27 Revised:2020-01-16 Published:2020-03-15 Online:2020-03-15
  • Contact: XIA Tian,E-mail:xiatian76@163.com E-mail:63442332@qq.com
  • Supported by:
     

Abstract: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease for women of childbearing age. Ovulation stimulation is the main treatment of PCOS, and clomiphene citrate (CC) is the first-line medicine of ovulation stimulant. However, some patients are not sensitive to CC, so-called clomiphene resistant PCOS (CCR-PCOS). Clinically, pre-treatments should be done in the early stage of ovulation induction in order to achieve a good therapeutic effect, including lifestyle management, improvement of insulin resistance, reduction of androgens and lipid levels, etc., the single or combined stimulation therapy was then selected among letrozole, gonadotropin and laparoscopic ovarian drilling. It is worth noting that IVF can be used to facilitate pregnancy in those CCR-PCOS patients with the first- and second-line ovulation induction failure or with other IVF indications (such as advanced age, fallopian tube factors or male factors leading to infertility). The pregnancy-promoting strategies of CCR-PCOS patients were reviewed in this paper.

Key words: Clomiphene;Polycystic ovary syndrome;Triazoles;Gonadotropins;Laparoscopes;, Ovary;, Ovulation induction;, Infertility;, Ovarian hyperstimulation syndrome

CLC Number: